News & Updates

Add-on palbociclib may overcome resistance to anti-HER2 Tx, ET in HR+, HER2+ mBC

15 Jan 2025 by

The addition of the CDK4/6 inhibitor palbociclib to anti-HER2 and endocrine therapy (ET) significantly improves progression-free survival (PFS) in patients with hormone receptor-positive, HER-positive (HR+, HER+) metastatic breast cancer (mBC) in the first-line setting, according to the results of the phase III AFT-38 PATINA trial.

Add-on palbociclib may overcome resistance to anti-HER2 Tx, ET in HR+, HER2+ mBC

15 Jan 2025

Sequential oral meds fall short, insulin remains best for gestational diabetes

14 Jan 2025 by

In the management of gestational diabetes, a sequential oral glucose-lowering medication strategy of metformin and additional glyburide, if needed, failed to demonstrate noninferiority to insulin, according to a study.

Sequential oral meds fall short, insulin remains best for gestational diabetes

14 Jan 2025

Radiofrequency ablation of vaginal canal relieves GSM symptoms

12 Jan 2025

The use of radiofrequency ablation of the vaginal canal by the MorpheusV applicator helps reduce symptoms of genitourinary syndrome of menopause (GSM), which include burning, dryness, dyspareunia, and irritative lower urinary tract symptoms, according to a study.

Radiofrequency ablation of vaginal canal relieves GSM symptoms

12 Jan 2025

Maternal NAFLD ups risk of adverse pregnancy outcomes

09 Jan 2025

Pregnant women with nonalcoholic fatty liver disease (NAFLD) face a greater risk of adverse pregnancy events, suggests a genome-wide association study.

Maternal NAFLD ups risk of adverse pregnancy outcomes

09 Jan 2025

Gestational hypertension, preeclampsia, and eclampsia associated with future neurological disorders

06 Jan 2025 by

Gestational hypertension, preeclampsia, and eclampsia were associated with an increased risk of new-onset migraine, headache, epilepsy, sleep disorder, or mental fatigue within months to years after giving birth, a Swedish study found.

Gestational hypertension, preeclampsia, and eclampsia associated with future neurological disorders

06 Jan 2025

Enzalutamide demonstrates modest activity in granulosa cell ovarian tumours

24 Dec 2024

The use of the antiandrogen enzalutamide in patients with granulosa cell ovarian tumour (GCT) falls short in terms of significant radiological response or clinical benefit, according to a phase II trial.

Enzalutamide demonstrates modest activity in granulosa cell ovarian tumours

24 Dec 2024

Novel PD-1 inhibitor shows activity against PD-L1 positive recurrent or metastatic cervical cancer

22 Dec 2024

Enlonstobart, a fully humanized and high-affinity anti-PD-1 immunoglobulin G4 monoclonal antibody, shows therapeutic potential in patients with PD-L1 positive recurrent or metastatic cervical cancer (r/mCC), while having an acceptable safety profile, according to an open-label phase II study.

Novel PD-1 inhibitor shows activity against PD-L1 positive recurrent or metastatic cervical cancer

22 Dec 2024

Add-on mifepristone for early pregnancy loss lowers chances of treatment failure

16 Dec 2024

In the treatment of women with early pregnancy loss, adding mifepristone to misoprostol helps reduce the incidence of treatment failure as compared with misoprostol alone, according to a retrospective study.

Add-on mifepristone for early pregnancy loss lowers chances of treatment failure

16 Dec 2024

Hyperthermic intraperitoneal chemotherapy beneficial in recurrent ovarian cancer

11 Dec 2024

Administering hyperthermic intraperitoneal chemotherapy (HIPEC) during cytoreductive surgery for recurrent ovarian cancer helps prolong overall survival, according to the results of the phase III open-label CHIPOR trial.

Hyperthermic intraperitoneal chemotherapy beneficial in recurrent ovarian cancer

11 Dec 2024

Endocrine therapy for breast cancer induces menopausal symptoms but mitigates depression

04 Dec 2024

Breast cancer patients undergoing adjuvant endocrine therapy appear to experience symptoms similar in type and intensity to those of symptomatic menopausal women, according to a retrospective study. However, the use of aromatase inhibitors is associated with less severe depressive symptoms.

Endocrine therapy for breast cancer induces menopausal symptoms but mitigates depression

04 Dec 2024

News & Updates

Filter by Specialty:

Specialty:

Add-on palbociclib may overcome resistance to anti-HER2 Tx, ET in HR+, HER2+ mBC

Add-on palbociclib may overcome resistance to anti-HER2 Tx, ET in HR+, HER2+ mBC

Sequential oral meds fall short, insulin remains best for gestational diabetes

Sequential oral meds fall short, insulin remains best for gestational diabetes

Radiofrequency ablation of vaginal canal relieves GSM symptoms

Radiofrequency ablation of vaginal canal relieves GSM symptoms

Maternal NAFLD ups risk of adverse pregnancy outcomes

Maternal NAFLD ups risk of adverse pregnancy outcomes

Gestational hypertension, preeclampsia, and eclampsia associated with future neurological disorders

Gestational hypertension, preeclampsia, and eclampsia associated with future neurological disorders

Enzalutamide demonstrates modest activity in granulosa cell ovarian tumours

Enzalutamide demonstrates modest activity in granulosa cell ovarian tumours

Novel PD-1 inhibitor shows activity against PD-L1 positive recurrent or metastatic cervical cancer

Novel PD-1 inhibitor shows activity against PD-L1 positive recurrent or metastatic cervical cancer

Add-on mifepristone for early pregnancy loss lowers chances of treatment failure

Add-on mifepristone for early pregnancy loss lowers chances of treatment failure

Hyperthermic intraperitoneal chemotherapy beneficial in recurrent ovarian cancer

Hyperthermic intraperitoneal chemotherapy beneficial in recurrent ovarian cancer

Endocrine therapy for breast cancer induces menopausal symptoms but mitigates depression

Endocrine therapy for breast cancer induces menopausal symptoms but mitigates depression